Description: Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
Home Page: sperotherapeutics.com
SPRO Technical Analysis
675 Massachusetts Avenue
Cambridge,
MA
02139
United States
Phone:
857 242 1600
Officers
| Name | Title |
|---|---|
| Dr. Ankit Mahadevia M.D., MBA | Co-Founder, Pres, CEO & Director |
| Mr. Satyavrat Shukla C.F.A. | CFO & Treasurer |
| Ted Jenkins | VP & Head of Investor Relations |
| Ms. Tamara Lynn Joseph L.L.M. | Chief Legal Officer |
| Mr. James P. Brady | Chief Human Resource Officer |
| Mr. Timothy Keutzer | Chief Devel. Officer |
| Dr. Ian A. Critchley | Head of Clinical Microbiology |
| Dr. Susannah Walpole Ph.D. | Head of Clinical Operations |
| Dr. Angela Talley M.D. | Sr. VP of Clinical Devel. |
| Dr. Kamal Hamed M.B.A., M.D., M.P.H. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7574 |
| Price-to-Sales TTM: | 9.9886 |
| IPO Date: | 2017-11-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |